MedTrace Logo

Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome

NCT01673308 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2016-05-11

No results posted yet for this study

Summary

This is a Phase II study to evaluate the efficacy of second-line lenalidomide monotherapy for myelodysplastic syndrome (MDS) patients who failed to hypomethylating agents.

Conditions

Interventions

DRUG

Lenalidomide

Lenalidomide 10 mg orally on days 1 to 21 of a 28-day cycle for at least 4 cycles until intolerance or disease progression.

Sponsors & Collaborators

  • Cooperative Study Group A for Hematology

    collaborator NETWORK

  • Ulsan University Hospital

    lead OTHER

Principal Investigators

  • Hawk Kim, M.D., Ph.D. · Ulsan University Hospital, University of Ulsan College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2015-11-30
Completion
2016-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01673308 on ClinicalTrials.gov